Latest News - Becton Dickinson
Top Corporates Hub
Becton Dickinson
BDX Expands U.S. Manufacturing With $19B Healthcare Investment
07.10.2026 14:55
BD plans a $19B U.S. investment, including $3B for manufacturing, to boost domestic medical consumables capacity and supply-chain resilience.
BD Strengthens Leadership in Peripheral Vascular Innovation with Positive AGILITY Trial Results
07.10.2026 12:00
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced positive nine-month results from the iliac cohort of the AGILITY Investigational Device Exemption trial evaluating the Revello™ Vascular Covered Stent. Presented at VIVA 2026 by Sean Lyden, M.D., global lead principal investigator for AGILITY, the results demonstrated strong safety and effectiveness outcomes in patients with iliac artery disease, a common form of peripheral artery disease
Trump says Becton Dickinson to invest $3 billion in US medical manufacturing
06.10.2026 04:52
Investing.com -- Becton Dickinson and Co (NYSE:BDX) has agreed to invest $3 billion to expand U.S. manufacturing of essential medical products, President Donald Trump said on Tuesday, as his administration pushes companies to bring more healthcare production onshore.
Becton Dickinson Q3 2026 Earnings Call: Complete Transcript
05.10.2026 06:35
Becton Dickinson (NYSE:BDX) held its third-quarter earnings conference call on Thursday. Below is the complete transcript from the call. This content is powered by Benzinga APIs. For comprehensive financial data and
Here's Why You Should Retain BDX Stock in Your Portfolio for Now
28.09.2026 15:15
Becton, Dickinson's MedTech transformation, innovation pipeline and strategic partnerships support growth despite reimbursement and macroeconomic pressures.
Waters: Positive Momentum Rides High Again
23.09.2026 14:03
Waters has rebounded sharply, with shares rising from $300 to $425 on solid organic and acquired sales growth. Click to read more about the WAT stock here.
How Far Can BSX Stock Swing After Losing More Than Half Its Value?
22.09.2026 13:29
Boston Scientific (BSX) stock has fallen 55.5% over the past twelve months, and at $43.72 it trades barely above its 52-week low of $42.63. The options market now prices a likely one-year range from $28.46 to $67.16 a share. That band is wide, but it is close to how much the stock has already been moving.
Why Is Becton Dickinson (BDX) Facing Fresh SEC And Litigation Pressure?
20.09.2026 10:09
Becton Dickinson (NYSE:BDX) reached an SEC cease and desist settlement over past Alaris infusion pump risk disclosures, including a civil penalty and creation of a Fair Fund for investors. Subsidiary C.R. Bard recently faced a plaintiff verdict in Bard PowerPort litigation, with thousands of related product liability cases still pending. The Alaris disclosure settlement and Bard PowerPort verdict both tie into a wider pattern of legal and compliance pressures our research tracks. We have...
BDX Deploys Vmax 160 to Advance Intelligent Pharmacy Automation
15.09.2026 15:21
BD expands U.S. pharmacy automation with Vmax 160 at Fairview to handle complex specialty and refrigerated medications.
BD Advances Intelligent Robotics to Transform the Future of Pharmacy Care at Fairview
14.09.2026 10:50
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Fairview Health Services has become the first health system in the United States to deploy the BD Vmax 160, a next generation pharmacy automation robot designed to help health systems manage the increasing complexity of specialty therapies and refrigerated medicines in high-volume, centralized outpatient pharmacy operations.
BSX Stock: Is It Time To Buy Or Sell Puts?
09.09.2026 18:06
Trading near $45 a share, Boston Scientific (BSX) sits roughly 58% below its 52-week peak. Instead of buying the dip outright, selling cash-secured put options allows investors to generate immediate income while locking in an even deeper entry point. Sell a put option on BSX expiring 9/17/2027, with a strike price of $30.
Becton, Dickinson and Company (BDX) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
09.09.2026 13:47
Becton, Dickinson and Company (BDX) Wells Fargo 21st Annual Healthcare Conference September 9, 2026 8:00 AM EDTCompany ParticipantsThomas Polen - President,...
Becton Dickinson & Co's Dividend Analysis
09.09.2026 11:01
Becton Dickinson & Co (NYSE:BDX) recently announced a total dividend of $1.05 per share, with the ex-dividend date set for 2026-09-09. This cash dividend is payable on 2026-09-30. As investors look forward to this upcoming payment, the spotlight also shines on the company's dividend history, yield, and growth rates.
Becton Dickinson (BDX) Becomes Founding Sponsor Of Hazardous Drug Data Consortium
03.09.2026 03:26
Becton Dickinson (NYSE:BDX) has become a founding sponsor of a new Medicinal Hazard Data Standardization Consortium focused on hazardous drug information. The global initiative aims to create standardized Medicinal Hazard Data Sheets to reduce data fragmentation and support safer handling of hazardous medicines for healthcare workers. Several major healthcare companies are joining BD in the consortium, which is expected to influence future regulatory and clinical best practice...
B of A Securities Maintains Neutral on Becton Dickinson, Raises Price Target to $200
31.08.2026 13:39
B of A Securities analyst Travis Steed maintains Becton Dickinson (NYSE:BDX) with a Neutral and raises the price target from $185 to $200.
Becton Dickinson (BDX) Could Be 1% Overvalued As PREVENT Trial Enrollment Ends
22.08.2026 00:10
Becton Dickinson (BDX) is in focus after announcing completion of patient enrollment in its PREVENT clinical trial for Phasix Mesh, a potential first in class option for preventing incisional hernias. See our latest analysis for Becton Dickinson. The PREVENT milestone comes after a series of recent updates around Becton Dickinson, including new quality leadership appointments, conference appearances and a recall-related correction notice. It also comes against a backdrop of a 30 day share...
Becton, Dickinson And Co. Completes Enrollment In PREVENT Clinical Trial Evaluating Phasix Mesh For Prevention Of Incisional Hernias
12.08.2026 06:54
Enrollment completed in the first large-scale randomized study evaluating Phasix™ Mesh for incisional hernia prevention, a significant unmet need following abdominal surgeryFRANKLIN LAKES, N.J., Aug. 12, 2026
Becton Dickinson (BDX) Stock Sees Modest Fair Value Lift After Mixed Analyst Views
09.08.2026 05:10
Becton Dickinson has seen its analyst fair value estimate move from US$181.23 to US$189.58, signaling a refreshed price target framework that investors are watching closely. This shift reflects how recent research is weighing the solid fiscal Q3 beat, product updates, and mixed views on 2027 utilization and margin risk. As you read on, you will see how these moving pieces shape the evolving narrative around Becton Dickinson and what that could mean for your own assessment of the stock. Stay...
Why Becton Dickinson (BDX) Is Up 6.8% After Q3 Beat And GLP-1 Delivery Partnerships
09.08.2026 00:20
Becton, Dickinson and Company recently reported third-quarter fiscal 2026 results, with sales rising to US$4,983 million while net income fell to US$377 million, and modestly raised its full-year outlook for low single-digit plus GAAP revenue growth. Alongside these earnings, BD highlighted strong momentum in biologic drug delivery and GLP-1–related partnerships, including a new semaglutide pen collaboration with EMS in Brazil, underscoring the growing role of its Vystra Injection Pen...
Becton Dickinson & Co (BDX) (Q3 2026) Earnings Call Highlights: Strong Revenue Growth and ...
08.08.2026 03:04
BDX beats expectations with 4.4% FX-neutral revenue growth, raises full-year EPS guidance, and outlines strategic plans to navigate fiscal 2027 headwinds.